Advertisement

Topics

Companies Related to "Keytruda with Pfizer Inlyta beats Sutent most common" [Most Relevant Company Matches] RSS

05:43 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Keytruda with Pfizer Inlyta beats Sutent most common" found in our extensive corporate database of over 50,000 company records.

Showing "Keytruda with Pfizer Inlyta beats Sutent most common" Companies 1–25 of 234

Relevant

Cureline, Inc

Cureline is a global biosample management company providing effective solutions for human tissue acquisition and related histology services. It was founded by a group of scientists and business development professionals who established the biorepository for SUGEN and participated in the development of Sutent (Pfizer Inc). Cureline has developed multinational collaborations and has implemented pro...


The Pfizer Foundation

The Pfizer Foundation is a charitable organization established by Pfizer Inc. The Foundation is a separate and independent tax-exempt organization. The Foundation’s mission is to promote access to quality health care, to nurture innovation, and to support the community involvement of Pfizer people.

Renata Limited

Historical High-Lights: Founded in 1972 as a subsidiary of Pfizer Inc. Ownership transferred from Pfizer Inc. to local institutions and the general public in 1993. Company name subsequently changed from Pfizer Laboratories (Bangladesh) Limited to Renata Limited.


Pfizer Ophthalmics

Pfizer Ophthalmics, a division of Pfizer Inc, is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. Its current product line includes the most presc...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale ...

Common Sense Ltd.

Common Sense Ltd. is a leading developer of indicators utilizing common hygienic products such as panty-liners, tampons and diapers as a platform for non-intrusive diagnosis and health condition monitoring. Common Sense has, and will continue to introduce a wide range of "future innovative panty-liners" which extend the current, simple hygiene product to a value added health-monitoring panty-liner...

Pfizer Consumer Healthcare

Centrum Silver

Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in...

Bristol-Myers Squibb-Pfizer Alliance

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

Common Sense Media

Common Sense Media is dedicated to improving the lives of kids and families by providing the trustworthy information, education, and independent voice they need to thrive in a world of media and technology. We exist because our kids are growing up in a culture that profoundly impacts their physical, social, and emotional well-being. We provide families wit...

Bristol-Myers Squibb Company and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an investigational oral anticoagulant discovered by Bristol-Myers Squibb being studied for the prevention and treatment of a broad range of venous and arterial thrombotic conditions. This global alliance combines Bristol-Myers Squibb's lon...

Pfizer

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people and their valued animals. Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, ...

Pfizer Inc. and Astellas Pharma Inc.

In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and Astellas (TSE: 4503) entered into a global agreement to jointly develop and commercialize enzalutamide. The companies jointly commercialize XTANDI in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United S...

Common Good

Common Voices

SAFE IN COMMON

AMS

AMS was founded in 1972 by Robert Buuck, Gerald Timm, Ph.D., William Bradley, M.D. and F. Brantley Scott, M.D. That year, Dr. Scott implanted the first urinary sphincter for incontinence.Company engineers then developed the first inflatable penile prosthesis for erectile dysfunction. In its early days, AMS also built the foundation for its strong physician relationships by developing surgical semi...

Veterans for Common Sense

Common Cause and Public Campaign

Common Sense Advisory

Common Ground Health Clinic

Pfizer Inc.

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients ...


More From BioPortfolio on "Keytruda with Pfizer Inlyta beats Sutent most common"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks